ALEC

Alector Inc.distress 5/10 · elevated risk

$1.50-2%today-55% from 52w high

alector.com103 employeesFounded 2013South San Francisco, CABiotechnology

Neurology 3

Lead: frontotemporal dementia with progranulin gene mutation · target Sortilin/PGRN

Revenue

pre-revenue

Liquidity

$207M

Runway

1.2 yrs

Shares 1y

+10%

Price & events

-21.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.6%

+2.4%

-17.8%

-38.1%

-22.4%

-15.4%

-77.1%

-95.4%

-90.0%

All

Overview

Market Cap: $167.09M
Enterprise Value: $98.42M
Volume: 23.10K
52 Week Range: $1.14 – $3.32
Total Shares: 111.03M
Float Shares: 93.80M
Short %: 5.45%
% Held by Insiders: 9.67%
% Held by Institutions: 82.20%
RVOL: 0.03x
Beta: 0.60

Pipeline stages · 3 programs

LatozinemabSortilin/PGRN

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

AL001, Open label - AL001Sortilin/PGRN

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

AL002

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 3 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2025-09-01	Phase 3	Latozinemab	Neurodegenerative Diseases	17	terminated
2025-09-01	Phase 3	AL001, Open label - AL001	Frontotemporal Dementia	119	terminated
2025-01-31	Phase 2	AL002	Alzheimer's Disease	197	terminated

Catalyst news & presentations · 5

late 2025 or early 2026Guided 40%readoutPhase 3latozinemab · Topline data expected.SEC 8-K
2026-08-10earningsEarningsEarnings releaseyahoo
2025-10-21trial discontinuedlatozinemab · Discontinuing open-label extension and continuation study for latozinemab following Phase 3 results.SEC 8-K
2025-01-09withdrawalAL002 · AbbVie terminates TREM2 program and co-development agreementSEC 8-K
2024-11-25trial discontinuedAL002 · Stopping long-term extension of INVOKE-2 Phase 2 trial.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 111,025,187 · 1 offerings/1y · 0 PIPEs

2026-05-078-Kmaterial_agreement
2026-05-07424B5offering
2026-04-30EFFECTshelf_effective
2026-03-12S-3shelf_registration
2024-12-06SC 13Gstrategic_stake
2024-11-148-Kmaterial_agreement
2024-11-12SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

hold · target $3 (+106% upside) · 5 analysts

2026-04-15Cantor FitzgeraldNeutral → Overweight
2026-03-10BTIGNeutral → Buy
2025-10-22William BlairOutperform → Market Perform
2025-10-22HC Wainwright & Co.Buy
2025-10-22Cantor FitzgeraldOverweight → Neutral
2025-10-22BTIGBuy → Neutral

Competitors — Sortilin/PGRN

ALZNAlzamend Neuro, Inc.$5M · D9

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.